Navigation Links
Australian Government Announces Survey To Tackle Childhood Obesity

Around 4,000 Australian children are to be weighed, measured and interviewed regarding their diet in a national survey designed to tackle //the growing menace of childhood obesity. The Australian Health department said that about 25 percent of the children aged between 7 and 15, are either overweight or obese.

This problem is increasing the incidence of heart disease and diabetes. Federal Health Minister Tony Abbott said that 4,000 children would take part in the national nutrition survey. "Helping consumers make informed choices about their lifestyle, particularly about the food they eat, is an important role for industry as well as government," he added.

The Australian Bureau of Statistics had revealed in February that 62 percent of men and 45 percent of women were either overweight or obese.

Mr Abbot said the results of this survey would be announced next year.
'"/>




Page: 1

Related medicine news :

1. Australian Scientists Silence Cancer Gene
2. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Australian Health funds stand accused
5. Australian Court Finds Man Guilty of Spreading HIV/AIDS
6. Australian Scientists Develop Novel Drug To Combat Inflammatory Diseases
7. Sale Of Bird Flu Vaccine to US Planned: Australian Firm
8. Hepatitis C Could Infect 800,000 Australians By 2020
9. Obesity Cost More Than The Australian Health Budget
10. Australian Snake Venom Can Arrest Bleeding During Surgery And Trauma
11. Fat Virus, Ad-36 Blamed For Obesity Epidemic In Australians
Post Your Comments:
(Date:5/30/2015)... The results of a 40+ year study ... potential to cause mesothelioma, regardless of the volume of ... the Surviving Mesothelioma website. , The study conducted ... Poland found that, among the 138 cases of mesothelioma ... all of them happened at plants that had, at ...
(Date:5/30/2015)... San Diego, CA (PRWEB) May 30, 2015 ... public is the lack of local healthcare options available. ... access to adequate healthcare. For those in rural areas ... those simply without health insurance or tired of paying ... announces new E-consults, connecting patients with licensed physicians via ...
(Date:5/30/2015)... 30, 2015 On Thursday, May ... Charles Simone and Dr. Evan Alley both of ... the Mesothelioma Experts’ series. The interview was part ... centers of excellence. Drs. Simone and Alley were ... Hesdorffer, with whom they discussed the mesothelioma program ...
(Date:5/30/2015)... May 30, 2015 Boston Scientific ... in punitive and compensatory damages to a transvaginal ... serious complications following implantation of the company’s Pinnacle ... rendered on May 28th in Delaware Superior Court, ... damages after the jury found that the implants ...
(Date:5/30/2015)... ProIntro Magnify contains 30 self-animating and minimalistic Titles including ... elegant opening title to any Final Cut Pro X ... layouts. ProIntro Magnify is created exclusively for Final Cut Pro ... Simply drag a preset into the FCPX timeline ... Inspector window then watch as ProIntro Magnify does the rest. ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2
... ATLANTA, Feb. 25 Billian,s HealthDATA continues ... while increasing the value of,current subscribers, licenses. ... their current online offering and continues to ... intelligence,ensuring that they have the most current ...
... DIEGO, Feb. 25 Imagenetix, Inc. (OTC Bulletin,Board: ... Sports,Medicine (FIMS) and its Executive Committee has selected ... FIMS,s goal since 1928,was to provide the best ... and,winter Olympic Games. Now it has expanded its ...
... , Easing concerns about pollution from manufacture ... In a finding that could help ease concerns about ... report that the manufacture of solar cells produces far ... report, the first comprehensive study on the pollutants produced ...
... ST. LOUIS, Feb. 25 Every Step Counts ... Louis Community,College - Forest Park will continue its ... assault. The organization will host "Walk In,Her Shoes" ... two US cities --,St. Louis and Atlanta. Designer ...
... Opportunities for Using Wireless ... Accuracy of Patient Care, WALTHAM, Mass., Feb. 25 ... LANs (WLANs) for enterprises and,service providers, will leverage its ... place February 24-28 in Orlando, FL, to,showcase how the ...
... and Increased Uptake of, CellCept Will Provide Effective ... ... WALTHAM, Mass., Feb. 25 Decision Resources, one of ... finds that the entry and uptake of high-priced branded,agents will ...
Cached Medicine News:Health News:Billian's HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence 2Health News:Billian's HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence 3Health News:International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as it's First and Only Official Joint and Muscle Topical Cream 2Health News:International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as it's First and Only Official Joint and Muscle Topical Cream 3Health News:American Chemical Society's Weekly PressPac -- Feb. 20, 2008 2Health News:American Chemical Society's Weekly PressPac -- Feb. 20, 2008 3Health News:American Chemical Society's Weekly PressPac -- Feb. 20, 2008 4Health News:American Chemical Society's Weekly PressPac -- Feb. 20, 2008 5Health News:American Chemical Society's Weekly PressPac -- Feb. 20, 2008 6Health News:American Chemical Society's Weekly PressPac -- Feb. 20, 2008 7Health News:American Chemical Society's Weekly PressPac -- Feb. 20, 2008 8Health News:American Chemical Society's Weekly PressPac -- Feb. 20, 2008 9Health News:Shoe Therapy Helps Survivors Celebrate Life After Abuse 2Health News:Colubris Demonstrates Wide-Ranging Mobility Solutions for Healthcare 2Health News:Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016 2
(Date:5/30/2015)... N.J. , May 30, 2015  Eisai Inc. announced ... which showed that eribulin met the study,s primary endpoint evaluating ... adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma. ... Annual Meeting of the American Society of Clinical Oncology (ASCO) ... ASCO press conference on Saturday, May 30, and also in ...
(Date:5/30/2015)... IRVING, Tex. , May 30, 2015 /PRNewswire/ ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the utility of Caris Molecular ... in facilitating comparisons between tumors that share histological ... of the American Society of Clinical Oncology (ASCO) ...
(Date:5/29/2015)... OTTAWA , May 29, 2015 /CNW/ - Alliance ... Canada, is recalling the health product Galenic Health ... levels of lead for adolescents and children. The ... limits for children, but within acceptable limits for ... used to relieve digestive upset and disturbances. Alliance ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
... POTTERS BAR, England, Oct. 25, 2011 Mylan Inc. (Nasdaq: ... has launched Rivastigmine Capsules POM, 1.5 mg, 3 mg, 4.5 ... of Novartis, Exelon ® Capsules, a treatment for dementia ... to launch a generic Rivastigmine formulation in the U.K. ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market to 2017 - Multiple Sclerosis, ... for Half the Market Value in ...
Cached Medicine Technology:Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 2Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 3Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 4Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 5Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 6Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 7Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 9Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 10Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 11Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 12Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 13Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 14Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 15Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 16Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 17Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 18Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 19Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 20
Colloidal Gold Conjugated, Rabbit anti-goat IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 12 OD...
Medicine Products: